Business
Ionis reports third quarter 2021 financial results and recent business achievements
Olezarsen (IONIS-APOCIII-L Rx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-L Rx) Phase 2 data to be presented at ACAAI Annual
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"Olezarsen (IONIS-APOCIII-L Rx) Phase 3 CORE study in patients with sHTG initiated\n Donidalorsen (IONIS-PKK-L Rx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track for year-end\n Tofersen Phase 3 VALOR study missed primary endpoint; signs of reduced disease progression observed across multiple secondary and exploratory endpoints\n Webcast today, November 3, 2021, at 11:30 a.m. Eastern Time\n\n\nCARLSBAD, Calif., Nov. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the three and nine months ended September 30, 2021 and recent business achievements.\n\n \n \n \n \n \n \n\n \n\"Among recent business highlights, we further expanded our broad late-stage pipeline to seven Phase 3 programs now that the olezarsen Phase 3 CORE study in patients with severe hypertriglyceridemia is underway. We were encouraged that while tofersen did not achieve the primary endpoint in the Phase 3 VALOR study, trends favoring tofersen were seen across multiple secondary and exploratory measures of disease progression in patients with SOD1-ALS. We also expanded our LICA platform capabilities by licensing technology from Bicycle Therapeutics,\" said Brett P. Monia, Ph.D., chief executive officer of Ionis. \"We are looking forward to multiple near-term catalysts, beginning with the presentation of donidalorsen Phase 2 data in patients with hereditary angioedema at the ACAAI Annual Meeting this weekend. We anticipate initiating the donidalorsen Phase 3 study before year-end. We also expect multiple catalysts in 2022, including results from the eplontersen Phase 3 study in patients with TTR polyneuropathy mid-year 2022. Furthermore, at our virtual investor day on December 9th, we look forward to outlining commercial preparations for our lead programs ahead of our first potential launch with eplontersen in patients with TTR polyneuropathy in 2023. Based on our anticipated near- and mid-term catalysts, we remain on track to have 12 or more products on the market in 2026.\"\nThird Quarter 2021 Financial Results \nThird quarter results reflect Ionis' focus on its strategic objectives $133 million in total revenues $185 million of operating expenses on a non-GAAP basis(1) and $219 million on a GAAP basis Net loss of $48 million on a non-GAAP basis(1) and $82 million on a GAAP bas...